Yüklüyor......
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight...
Kaydedildi:
| Yayımlandı: | Endocrinol Metab (Seoul) |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Korean Endocrine Society
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8258332/ https://ncbi.nlm.nih.gov/pubmed/34139800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2020.934 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|